B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma

Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501 Rosenwald, 2002, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, 346, 1937, 10.1056/NEJMoa012914 Davis, 2001, Constitutive nuclear factor kappa B activity is required for survival of activated B Cell-like diffuse large B cell lymphoma cells, J Exp Med, 194, 1861, 10.1084/jem.194.12.1861 Roschewski, 2014, Diffuse large B-cell lymphoma-treatment approaches in the molecular era, Nat Rev Clin Oncol, 11, 12, 10.1038/nrclinonc.2013.197 Ben-Neriah, 2011, Inflammation meets cancer, with NF-kappaB as the matchmaker, Nat Immunol, 12, 715, 10.1038/ni.2060 Staudt, 2010, Oncogenic activation of NF-kappaB, Cold Spring Harbor perspectives in biology, 2, a000109, 10.1101/cshperspect.a000109 Lam, 2005, Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling, Clin Cancer Res, 11, 28, 10.1158/1078-0432.28.11.1 Ngo, 2006, A loss-of-function RNA interference screen for molecular targets in cancer, Nature, 441, 106, 10.1038/nature04687 Thome, 2010, Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1, Cold Spring Harb Perspect Biol, 2, a003004, 10.1101/cshperspect.a003004 Lenz, 2008, Oncogenic CARD11 mutations in human diffuse large B cell lymphoma, Science, 319, 1676, 10.1126/science.1153629 Yang, 2014, Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms, Cancer Discov, 4, 480, 10.1158/2159-8290.CD-13-0915 Dubois, 2014, A catalytic-independent role for the LUBAC in NF-kappaB activation upon antigen receptor engagement and in lymphoma cells, Blood, 123, 2199, 10.1182/blood-2013-05-504019 Shaffer, 2012, Pathogenesis of human B cell lymphomas, Annu Rev Immunol, 30, 565, 10.1146/annurev-immunol-020711-075027 Lam, 2008, Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen, Proc Natl Acad Sci U S A, 105, 20798, 10.1073/pnas.0806491106 Yang, 2012, Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma, Cancer Cell, 21, 723, 10.1016/j.ccr.2012.05.024 Lenz, 2008, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proc Natl Acad Sci U S A, 105, 13520, 10.1073/pnas.0804295105 Ochiai, 2006, Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells, J Biol Chem, 281, 38226, 10.1074/jbc.M607592200 Care, 2014, SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity, Nucl Acids Res, 42, 7591, 10.1093/nar/gku451 Kuppers, 2005, Mechanisms of B-cell lymphoma pathogenesis, Nat Rev Cancer, 5, 251, 10.1038/nrc1589 Lenz, 2007, Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma, J Exp Med, 204, 633, 10.1084/jem.20062041 Ruminy, 2011, The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma, Leukemia, 25, 681, 10.1038/leu.2010.302 Liu, 2010, Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling, Immunity, 32, 778, 10.1016/j.immuni.2010.06.006 Dogan, 2009, Multiple layers of B cell memory with different effector functions, Nat Immunol, 10, 1292, 10.1038/ni.1814 Martin, 2002, Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory, Nat Immunol, 3, 182, 10.1038/ni752 Horikawa, 2007, Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors, J Exp Med, 204, 759, 10.1084/jem.20061923 Dal Porto, 2004, B cell antigen receptor signaling 101, Mol Immunol, 41, 599, 10.1016/j.molimm.2004.04.008 Reth, 1989, Antigen receptor tail clue, Nature, 338, 383, 10.1038/338383b0 Rowley, 1995, Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation, J Biol Chem, 270, 11590, 10.1074/jbc.270.19.11590 Rawlings, 1996, Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases, Science, 271, 822, 10.1126/science.271.5250.822 Davis, 2010, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, 463, 88, 10.1038/nature08638 Brunner, 2005, Bruton’s tyrosine kinase is involved in innate and adaptive immunity, Histol Histopathol, 20, 945 Lam, 1997, In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death, Cell, 90, 1073, 10.1016/S0092-8674(00)80373-6 Kraus, 2004, Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer, Cell, 117, 787, 10.1016/j.cell.2004.05.014 Monroe, 2006, ITAM-mediated tonic signalling through pre-BCR and BCR complexes, Nat Rev Immunol, 6, 283, 10.1038/nri1808 Srinivasan, 2009, PI3 kinase signals BCR-dependent mature B cell survival, Cell, 139, 573, 10.1016/j.cell.2009.08.041 Chen, 2013, SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas, Cancer Cell, 23, 826, 10.1016/j.ccr.2013.05.002 Kloo, 2011, Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci U S A, 108, 272, 10.1073/pnas.1008969108 Tolar, 2009, The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens, Immunity, 30, 44, 10.1016/j.immuni.2008.11.007 Gazumyan, 2006, Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization, J Exp Med, 203, 1785, 10.1084/jem.20060221 Busman-Sahay, 2013, Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs, PLoS One, 8, e54938, 10.1371/journal.pone.0054938 Xu, 2005, Lyn tyrosine kinase: accentuating the positive and the negative, Immunity, 22, 9 Compagno, 2009, Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma, Nature, 459, 717, 10.1038/nature07968 Srinivasula, 2011, A20: more than one way to skin a cat, Mol Cell, 44, 511, 10.1016/j.molcel.2011.11.004 Agathangelidis, 2012, Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies, Blood, 119, 4467, 10.1182/blood-2011-11-393694 Catera, 2008, Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation, Mol Med, 14, 665, 10.2119/2008-00102.Catera Chu, 2010, Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin, Blood, 115, 3907, 10.1182/blood-2009-09-244251 Duhren-von Minden, 2012, Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling, Nature, 489, 309, 10.1038/nature11309 Sebastian, 2012, Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype, Am J Pathol, 181, 1879, 10.1016/j.ajpath.2012.07.028 Benschop, 2001, Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation, J Immunol, 167, 4172, 10.4049/jimmunol.167.8.4172 Gross, 2009, Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance, J Immunol, 182, 5382, 10.4049/jimmunol.0803941 Ngo, 2011, Oncogenically active MYD88 mutations in human lymphoma, Nature, 470, 115, 10.1038/nature09671 Jiang, 2006, Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis, Proc Natl Acad Sci U S A, 103, 10961, 10.1073/pnas.0603804103 Leadbetter, 2002, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors, Nature, 416, 603, 10.1038/416603a Chaturvedi, 2008, The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens, Immunity, 28, 799, 10.1016/j.immuni.2008.03.019 O’Neill, 2009, Endocytic sequestration of the B cell antigen receptor and toll-like receptor 9 in anergic cells, Proc Natl Acad Sci U S A, 106, 6262, 10.1073/pnas.0812922106 Wang, 2014, Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance, J Exp Med, 211, 413, 10.1084/jem.20131424 Schmitz, 2014, Oncogenic mechanisms in Burkitt lymphoma, Cold Spring Harb Perspect Biol, 4 Schmitz, 2012, Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics, Nature, 490, 116, 10.1038/nature11378 Sander, 2012, Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis, Cancer Cell, 22, 167, 10.1016/j.ccr.2012.06.012 Murre, 1989, A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins, Cell, 56, 777, 10.1016/0092-8674(89)90682-X Pfeifer, 2013, PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma, Proc Natl Acad Sci U S A, 110, 12420, 10.1073/pnas.1305656110 Young, 2013, Targeting pathological B cell receptor signalling in lymphoid malignancies, Nat Rev Drug Discov, 12, 229, 10.1038/nrd3937 Wilson, 2012, The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study, ASH Abstract Furman, 2014, Ibrutinib resistance in chronic lymphocytic leukemia, N Engl J Med, 370, 2352, 10.1056/NEJMc1402716 Woyach, 2014, Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib, N Engl J Med, 370, 2286, 10.1056/NEJMoa1400029 Cheng, 2014, Functional Characterization of BTK mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors, Leukemia, 10.1038/leu.2014.263 Mathews Griner, 2014, High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci U S A, 111, 2349, 10.1073/pnas.1311846111 Ceribelli, 2014, Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors, Proc Natl Acad Sci U S A, 111, 11365, 10.1073/pnas.1411701111